Redcare Pharmacy stock gains as Deutsche Bank reiterates Buy rating

Published on 09/19/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock recently traded around EUR 60.90 as of September 18, 2026, after a rebound in the SDAX. Deutsche Bank Research continues to rate Redcare Pharmacy stock Buy with a triple-digit euro price target, highlighting perceived upside potential.

Flatlay mit Aktienzertifikat, ISIN-Karte, Pillenblistern und Stethoskop von oben — Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt Flatlay mit Aktienzertifikat, ISIN-Karte und markenfreien Apotheken-Utensilien, Illustration mit AI erstellt.

Redcare Pharmacy stock (ISIN NL0012044747) recently traded at around EUR 60.90 on Xetra as of September 18, 2026, after a notable rebound in the SDAX segment of the German market. According to FinanzNachrichten, the shares had risen by about 1.67 percent on that day, extending gains from earlier in the week.

Analyst support underpins Redcare Pharmacy stock

One of the key drivers behind the recent move in Redcare Pharmacy stock is renewed support from analyst houses. Deutsche Bank Research reaffirmed its Buy rating on Redcare Pharmacy with a price target of EUR 103 in a note dated September 1, 2026, viewing the leadership change at the company as part of a broader strategic realignment with attractive long-term prospects, according to FinanzNachrichten. Earlier, Jefferies reiterated its Buy rating with a price target of EUR 97 on September 3, 2026, noting that despite some weaker trading in August, the structural growth story in online pharmacy remains intact, as reported by FinanzNachrichten.

The combination of these two price targets implies a significant upside from the recent level around EUR 60.90. Using the Deutsche Bank Research target of EUR 103, the implied potential appreciation is approximately 69.2 percent versus the September 18, 2026 closing region, while the Jefferies target of EUR 97 suggests a potential gain of about 59.3 percent from the same reference price. For investors, these large target spreads underline the extent to which banks see Redcare Pharmacy as a growth play within European e-commerce healthcare.

Volatile share performance and recent rebound

Despite the supportive analyst stance, Redcare Pharmacy stock has experienced pronounced volatility in recent weeks. On September 9, 2026, the shares fell by about 5 percent intraday and were the weakest performer in the SDAX, as described by an article on sharedeals.de summarized in the news overview of FinanzNachrichten. That decline extended a multi-week downward trend, reflecting profit-taking after a strong earlier rally.

However, from the start of the week of September 14, 2026, the share price rebounded sharply. One piece highlighted in the same overview reported that since Monday of that week, Redcare Pharmacy stock had climbed by about 17 percent, illustrating how quickly sentiment can reverse in a momentum-driven growth name, according to FinanzNachrichten. This swing from a 5 percent drop on September 9, 2026 to a double-digit percentage recovery within days underscores the risk factor of volatility that investors need to factor into their positioning.

Strategic and regulatory context: PoPP and e-prescriptions

Beyond day-to-day price moves, Redcare Pharmacy is also benefiting from structural developments in the German and European digital health landscape. On September 7, 2026, the company welcomed further progress on the so-called PoPP framework, which addresses digital identity and access for patients in remote healthcare settings. According to an EQS-News release summarized on FinanzNachrichten, a new pre-specification creates the basis for a health ID in telemedicine and remote pharmacy services.

Separate reports on September 8, 2026 from specialist outlets highlighted that Redcare Pharmacy sees its digital e-prescription access as secured under the emerging PoPP architecture, a key operational factor in ensuring that patients can seamlessly submit prescriptions online, according to FinanzNachrichten. For investors, this regulatory progress helps mitigate one important risk: the possibility that changes in digital health infrastructure could limit the ability of online pharmacies to receive and process prescriptions. Instead, the current direction appears to anchor Redcare Pharmacy more firmly in the evolving digital ecosystem.

Leadership change and long-term positioning

Strategic leadership changes have also shaped the investment narrative. On August 28, 2026, reports noted that Peter Schmid von Linstow would become the new chief executive officer (CEO) of Redcare Pharmacy, signaling a planned transition at the top of the company. According to a retail-industry news item summarized by FinanzNachrichten, this succession plan is part of a broader organizational reshaping.

Deutsche Bank Research explicitly referenced this leadership change in its September 1, 2026 note, indicating that the CEO shift appears to be part of an extensive transformation and does not alter the bank's constructive long-term view on Redcare Pharmacy, as reported by FinanzNachrichten. For shareholders, this suggests that the company aims to strengthen its management bench while continuing to pursue growth in European online pharmacy and healthcare logistics.

Risk factors: valuation and volatility

While analyst targets sit clearly above the current share price, risk comments in recent coverage focus on valuation and market swings. Articles cited in the news overview note that the stock had at times been described as expensive following strong gains, and the 5 percent drop on September 9, 2026 was linked to worries about stretched valuation in a market that had been pricing in substantial growth, according to FinanzNachrichten. The 17 percent rebound since the start of the week of September 14, 2026 also means that short-term traders are actively influencing price action, making entry points more sensitive.

Another relevant risk highlighted in commentary is that the online pharmacy market remains competitive, with regulatory changes, reimbursement schemes and customer acquisition costs all affecting profitability. As analysts at Jefferies pointed out in their September 3, 2026 note, weaker developments in August illustrated that short-term operating trends can lag behind the long-term growth vision, even though the structural story remains positive for Redcare Pharmacy, according to FinanzNachrichten. Investors therefore need to weigh these operational and regulatory factors alongside the upside potential implied by the high analyst targets.

Stock level and market data

As of September 18, 2026, indicative quotes in the FinanzNachrichten overview showed bid and ask prices for Redcare Pharmacy stock around EUR 60.30 and EUR 61.20 during that trading day, with another set around EUR 60.50 and EUR 61.00, suggesting that the market was consolidating slightly below the mid-60 euro zone. Per the same overview on FinanzNachrichten, the shares were among the actively traded SDAX constituents on that day.

In this environment, Redcare Pharmacy stock remains a notable name for investors interested in European e-commerce healthcare. The combination of a recent price around EUR 60.90 on September 18, 2026, double-digit percentage rebound since the start of the week of September 14, 2026, and analyst price targets of EUR 97 and EUR 103 creates a wide band between current trading and perceived fair value. The volatility seen in early September 2026, with a 5 percent decline followed by a roughly 17 percent recovery, illustrates both opportunity and risk in the stock.